Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease

Eur J Med Chem. 2022 Aug 5:238:114503. doi: 10.1016/j.ejmech.2022.114503. Epub 2022 Jun 3.

Abstract

Recently, the discovery of multifunctional molecules that target different factors in the treatment of dementia is a significant research area. Both PDE4 and AChE inhibitors display improvement in cognitive and memory function. In this study, twenty-eight novel 2,3-dihydro-1H-inden-1-ones were designed, synthesized, and evaluated as catechol ether-based dual PDE4/AChE inhibitors to treat Alzheimer's disease (AD). Among these compounds, 12C bearing a 2-(piperidin-1-yl)ethoxy group at the 6-position of indanone ring displayed satisfactory inhibitory activities and selectivity against AChE (IC50 = 0.28 μM) and PDE4D (IC50 = 1.88 μM). Compared with donepezil, 12C revealed a comparable neuroprotective effect. Moreover, 12C exhibited comparable AChE inhibitory activity with donepezil in the hippocampus of AD model mice. Interestingly, 12C displayed more potent anti-neuroinflammation than the donepezil and drug combination (donepezil + rolipram) groups. These results suggest that 12C is a promising multifunctional agent for the treatment of AD.

Keywords: 2,3-Dihydro-1H-inden-1-ones; AChE inhibitors; Alzheimer's disease; PDE4 inhibitors; Selectivity.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease* / drug therapy
  • Animals
  • Cholinesterase Inhibitors / pharmacology
  • Cholinesterase Inhibitors / therapeutic use
  • Donepezil / pharmacology
  • Drug Design
  • Indenes / chemistry*
  • Indenes / pharmacology
  • Mice
  • Neuroinflammatory Diseases
  • Phosphodiesterase 4 Inhibitors* / pharmacology
  • Phosphodiesterase 4 Inhibitors* / therapeutic use
  • Structure-Activity Relationship

Substances

  • Cholinesterase Inhibitors
  • Indenes
  • Phosphodiesterase 4 Inhibitors
  • Donepezil
  • Acetylcholinesterase